BioVersys AG Virtual KOL Event: BV100 Shows Survival Benefit in Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter. What Does that Mean for Patients? A Perspective from the US and from Asia.
| DATE: | May 7, 2025 |
|---|---|
| TIME: | 8:30 AM EDT |
| LOCATION: | Virtual |
About The Event
Join BioVersys for a virtual key opinion leader (KOL) event featuring Professor David Paterson (ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore) and Dr. Andrew Shorr, MD, MPH, MBA (Medstar Washington Hospital Center, Georgetown University), who will join company management to discuss the unmet need and current treatment landscape for carbapenem resistant Acinetobacter baumannii (CRAB) pneumonia.
The event will review results from the Phase 2 study evaluating BV100 for the treatment of serious infections due to A. baumannii, demonstrating substantial survival benefit. BV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing an active uptake of rifabutin into A. baumannii.
A live question and answer session will follow the formal presentations.